TDP-43 as structure-based biomarker in amyotrophic lateral sclerosis.

Area of Science:

• Neuroscience
• Biomarker Discovery
• Proteinopathy Research

Background:

• Pathologic alterations of Transactivation response DNA-binding protein 43 kilo Dalton (TDP-43) are a key characteristic of amyotrophic lateral sclerosis (ALS).
• Investigating TDP-43's secondary structure in cerebrospinal fluid (CSF) may reveal diagnostic markers for neurodegenerative diseases.

Purpose of the Study:

• To analyze the secondary structure distribution of TDP-43 in the CSF of ALS patients.
• To compare TDP-43 secondary structure in ALS patients with those suffering from Parkinson's disease (PD) and healthy controls (Ctrl).
• To evaluate the potential of TDP-43 misfolding as a biomarker for ALS using immuno-infrared sensor technology.

Main Methods:

• Utilized immuno-infrared sensor technology to analyze TDP-43 secondary structure distribution.
• Collected CSF samples from ALS patients (n=36), PD patients (n=30), and controls (n=24).
• Performed comparative analysis of TDP-43 structural patterns across the three groups.

Main Results:

• ALS patients showed distinct TDP-43 secondary structure distributions compared to PD and Ctrl groups.
• The analysis achieved high sensitivity and specificity in discriminating ALS patients: 89%/77% vs. PD and 89%/83% vs. Ctrl.
• TDP-43 misfolding, as measured by the sensor technology, showed significant differences in ALS.

Conclusions:

• TDP-43 misfolding detected via immuno-infrared sensor technology shows potential as a diagnostic biomarker for ALS.
• This method offers a promising approach for differentiating ALS from other neurological conditions like PD.
• Further validation is warranted to establish TDP-43 as a reliable biomarker for ALS diagnosis.